nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

15.03.2022 | Original Article

¹⁸F- or ¹⁷⁷Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention

verfasst von: Hongsheng Li, Shimin Ye, Li Li, Jiawei Zhong, Qingsong Yan, Yuhua Zhong, Pengju Feng, Kongzhen Hu

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Fibroblast activation protein (FAP) has become a promising cancer-related target for diagnosis and therapy. The aim of this study was to develop a bivalent FAP ligand for both diagnostic PET imaging and endoradiotherapy.

Methods

We synthesized a bivalent FAP ligand (ND-bisFAP) and labeled it with ¹⁸F or ¹⁷⁷Lu. FAP-positive A549-FAP cells were used to study competitive binding to FAP, cellular internalization, and efflux properties in vitro. Micro-PET imaging with [¹⁸F]AlF-ND-bisFAPI was conducted in mice bearing A549-FAP or U87MG tumors. Biodistribution and therapeutic efficacy of [¹⁷⁷Lu]Lu-ND-bisFAPI were conducted in mice bearing A549-FAP tumors.

Results

The FAP binding affinity of ND-bisFAPI is 0.25 ± 0.05 nM, eightfold higher in potency than the monomeric DOTA-FAPI-04 (IC₅₀ = 2.0 ± 0.18 nM). In A549-FAP cells, ND-bisFAPI showed specific uptake, a high internalized fraction, and slow cellular efflux. Compared to the monomeric [¹⁸F]AlF-FAPI-42, micro-PET imaging with [¹⁸F]AlF-ND-bisFAPI showed higher specific tumor uptake and retention for at least 6 h. Biodistribution studies showed that [¹⁷⁷Lu]Lu-ND-bisFAPI had higher tumor uptake than [¹⁷⁷Lu]Lu-FAPI-04 at the 24, 72, 120, and 168 h time points (all P < 0.01). [¹⁷⁷Lu]Lu-ND-bisFAPI delivered fourfold higher radiation than [¹⁷⁷Lu]Lu-FAPI-04 to A549-FAP tumors. For the endoradiotherapy study, 37 MBq of [¹⁷⁷Lu]Lu-ND-bisFAPI significantly reduced tumor growth compared to the same dose of [¹⁷⁷Lu]Lu-FAPI-04. Half of the dose of [¹⁷⁷Lu]Lu-ND-bisFAPI (18.5 MBq) has comparable median survival as 37 MBq of [¹⁷⁷Lu]Lu-FAPI-04 (37 vs 36 days).

Conclusion

The novel bivalent FAP ligand was developed as a theranostic radiopharmaceutical and showed promising properties including higher tumor uptake and retention compared to the established radioligands [¹⁸F]AlF-FAPI-42 and [¹⁷⁷Lu]Lu-FAPI-04. Preliminary experiments with ¹⁸F- or ¹⁷⁷Lu-labeled ND-bisFAPI showed promising imaging properties and favorable anti-tumor responses.

Nur mit Berechtigung zugänglich

Scanlan MJ, Raj BKM, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of fibroblast activation protein α, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994;91:5657–61.CrossRef

Bušek P, Mal R, Šedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol. 2004;36:408–21.CrossRef

Šimková A, Bušek P, Šedo A, Konvalinka J. Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications. Biochim Biophys Acta Proteins Proteomics. 2020;1868(7):140409.CrossRef

Busek P, Mateu R, Zubal M, Kotackova L, Sedo A. Targeting fibroblast activation protein in cancer–prospects and caveats. Front Biosci (Landmark Ed). 2018;23(10):1933–68.CrossRef

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.CrossRef

Wang S, Zhou X, Xu X, Ding J, Liu S, Hou X, et al. Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05470-5.CrossRefPubMedPubMedCentral

Zhao L, Niu B, Fang J, Pang Y, Li S, Xie C, et al. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of ⁶⁸Ga-labeled FAPI dimer. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.263016.CrossRefPubMedPubMedCentral

Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Kazuhiro Ooe K, et al. Fibroblast activation protein targeted therapy using [¹⁷⁷Lu]FAPI-46 compared with [²²⁵Ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05554-2.CrossRefPubMedPubMedCentral

Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, biodistribution and preliminary dosimetry in peptide-targeted radionuclide Therapy (PTRT) of diverse adenocarcinomas using ¹⁷⁷Lu-FAP-2286: first-in-human results. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.120.259192.CrossRefPubMedPubMedCentral

10.

Xu M, Zhang P, Ding J, Chen J, Huo L, Liu Z. Albumin binder–conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.262533.CrossRefPubMedPubMedCentral

11.

Wen X, Xu P, Shi M, Liu J, Zeng X, Zhang Y, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022;12:422–33.CrossRef

12.

Zhang P, Xu M, Ding J, Chen J, Zhang T, Huo L, et al. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05591-x.CrossRefPubMedPubMedCentral

13.

Ballal S, Yadav MP, Kramer V, Moon ES, Roesch F, Tripathi M, et al. A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:942–4.CrossRef

14.

Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of ⁶⁸Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61:1171–7.CrossRef

15.

Giesel FL, Adeberg S, Syed M, Lindner T, Jiménez-Franco LD, Mavriopoulou E, et al. FAPI-74 PET/CT using either ¹⁸F-AlF or cold-kit ⁶⁸Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62:201–7.CrossRef

16.

Toms J, Kogler J, Maschauer S, Daniel C, Schmidkonz C, Kuwert T, et al. Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an ¹⁸F-Labeled FAP inhibitor. J Nucl Med. 2020;61:1806–13.CrossRef

17.

Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421–9.CrossRef

18.

Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jäger D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.CrossRef

19.

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. ⁶⁸Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–5.CrossRef

20.

Hu K, Wang L, Wu H, Huang S, Tian Y, Wang Q, et al. [¹⁸F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [⁶⁸Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05646-z.CrossRefPubMedPubMedCentral

21.

Hu K, Li J, Wang L, Huang Y, Li L, Ye S, et al. Preclinical evaluation and pilot clinical study of [¹⁸F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts. Acta Pharm Sin B. 2021. https://doi.org/10.1016/j.apsb.2021.09.032.CrossRefPubMedPubMedCentral

22.

Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F]FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820–32.CrossRef

23.

Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, et al. ⁶⁸Ga-FAPI-04 versus ¹⁸F-FDG PET/CT in the detection of hepatocellular carcinoma. Front Oncol. 2021;11:1–10.

24.

Wang S, Zhou X, Xu X, Ding J, Liu T, Jiang J, et al. Dynamic PET/CT imaging of ⁶⁸Ga-FAPI-04 in Chinese subjects. Front Oncol. 2021;11:1–11.

25.

Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, et al. Fibroblast imaging of hepatic carcinoma with ⁶⁸Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging. 2021;48:196–203.CrossRef

26.

Kuten J, Levine C, Shamni O, Pelles S, Wolf I, Lahat G, et al. Head-to-head comparison of [⁶⁸Ga]Ga-FAPI-04 and [¹⁸F]FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05494-x.CrossRefPubMedPubMedCentral

27.

Huang Y, Li H, Ye S, Tang G, Liang Y, Hu K. Synthesis and preclinical evaluation of an Al¹⁸F radio fluorinated bivalent PSMA ligand. Eur J Med Chem. 2021;221:113502. https://doi.org/10.1016/j.ejmech.2021.113502.CrossRefPubMed

28.

Lieberman BP, Ploessl K, Wang L, Qu W, Zha Z, Wise DR, et al. PET imaging of glutaminolysis in tumors by ¹⁸F-(2S,4R)4- fluoroglutamine. J Nucl Med. 2011;52:1947–55.CrossRef

29.

Spetz J, Rudqvist N, Forssell-Aronsson E. Biodistribution and dosimetry of free ²¹¹At, ¹²⁵I- and ¹³¹I- in rats. Cancer Biother Radiopharm. 2013;28:657–64.CrossRef

30.

Yusufi N, Wurzer A, Herz M, D’Alessandria C, Feuerecker B, Weber W, et al. Comparative preclinical biodistribution, dosimetry, and endoradiotherapy in metastatic castration-resistant prostate cancer using ¹⁹F/¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I&T. J Nucl Med. 2021;62:1106–11.CrossRef

31.

Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, et al. Comparison study of [¹⁸F]FAl-NOTA-PRGD2, [¹⁸F]FPPRGD2, and [⁶⁸Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22:2415–22.CrossRef

32.

Zia NA, Cullinane C, Van Zuylekom JK, Waldeck K, McInnes LE, Buncic G, et al. A bivalent inhibitor of prostate specific membrane antigen radiolabeled with copper-64 with high tumor uptake and retention. Angew Chemie-Int Ed. 2019;58:14991–4.CrossRef

33.

Banerjee SR, Pullambhatla M, Shallal H, Lisok A, Mease RC, Pomper MG. A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Oncotarget. 2011;2:1244–53.CrossRef

34.

Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CCR, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1065–8.CrossRef

Titel: 18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention
verfasst von: Hongsheng Li
Shimin Ye
Li Li
Jiawei Zhong
Qingsong Yan
Yuhua Zhong
Pengju Feng
Kongzhen Hu
Publikationsdatum: 15.03.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05757-1

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

¹⁸F- or ¹⁷⁷Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

Synthesis, preclinical evaluation, and first-in-human study of Al18F-PSMA-Q for prostate cancer imaging

Correction to: Clinical summary of fibroblast activation protein inhibitor‑based radiopharmaceuticals: cancer and beyond

Ultrafast 30-s total-body PET/CT scan: a preliminary study

Spatiotemporal dynamics of brain function during the natural course in a dental pulp injury model

Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond

Identifying the individual metabolic abnormities from a systemic perspective using whole-body PET imaging